Qingdao Vland Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Qingdao Vland Biotech has a total shareholder equity of CN¥1.8B and total debt of CN¥642.7M, which brings its debt-to-equity ratio to 34.9%. Its total assets and total liabilities are CN¥3.0B and CN¥1.2B respectively. Qingdao Vland Biotech's EBIT is CN¥112.9M making its interest coverage ratio 11.4. It has cash and short-term investments of CN¥508.8M.
Key information
34.9%
Debt to equity ratio
CN¥642.68m
Debt
Interest coverage ratio | 11.4x |
Cash | CN¥508.82m |
Equity | CN¥1.84b |
Total liabilities | CN¥1.19b |
Total assets | CN¥3.03b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 603739's short term assets (CN¥1.1B) exceed its short term liabilities (CN¥1.1B).
Long Term Liabilities: 603739's short term assets (CN¥1.1B) exceed its long term liabilities (CN¥116.9M).
Debt to Equity History and Analysis
Debt Level: 603739's net debt to equity ratio (7.3%) is considered satisfactory.
Reducing Debt: 603739's debt to equity ratio has increased from 6% to 34.9% over the past 5 years.
Debt Coverage: 603739's debt is not well covered by operating cash flow (19.7%).
Interest Coverage: 603739's interest payments on its debt are well covered by EBIT (11.4x coverage).